U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

U.S.PATENTS

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	
(NOTION SUDMISSION UNIQUE 37 CFR 1.55)	
( Not for submission under 37 CFR 1.99)	

Application Number		10574384
Filing Date		
First Named Inventor	L. Wa	ng
Art Unit		
Examiner Name		
Attorney Docket Numb	er	CASM127366

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	late	Name of Pate of cited Docu	entee or Applicant iment	Pages,Columns,Lines Relevant Passages or Figures Appear				
	1	4577670	A	1986-03	-25	Moore						
	2	5586596	A	1996-12	-24	Freeman						
	3	6425433	B1	2002-07	-30	Hayes						
of warranda	h to ar	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add			
ii you wisi												
ii you wisi			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remov	•		
		Publication Number	U.S.P Kind Code <sup>1</sup>	Publica			entee or Applicant	Releva	Column ant Passa s Appea	s,Lines ages or		
Examiner	Cite	Publication Number	Kind	Publica		Name of Pate	entee or Applicant	Releva	Column	s,Lines ages or		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant iment	Releva	Column ant Pass s Appea	s,Lines ages or		
Examiner Initial*	Cite No		Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant iment	Releva	Column ant Pass s Appea	s,Lines ages or		
Examiner Initial*	Cite No 1		Kind Code <sup>1</sup>	Publica Date	citation	Name of Pate of cited Docu	entee or Applicant iment	Releve Figure	,Column ant Pass s Appea	s,Lines ages or	,Lines	

### 

	2	61 38769	JP	A	1986-02-24	Yasuo		
	3	0 930 114	EP	B1	1999-07-21	Muramatsu		
If you wie	h to a	dd additional For	nian Batant Dasu	mont citatio	n information s	please click the Add butto	n Add	
ii you wis	ii to a	du additional For			ERATURE DO		Remove	
			NON-F	AILMILII	EKATOKE DO	COMENTS	rtemere	
Examiner Initials*	taminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the it (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andior country where published.							n Ts
	1							
If you wis	h to a	dd additional non	-patent literature	document c	itation informa	tion please click the Add	button Add	
,					ER SIGNATUI			
				EXAMIN	ER SIGNATUR			
Examiner	Signa	ature				Date Considered		
						formance with MPEP 60 with next communication		а

1 See Kind Code of USPTO Patent Documents at How (LISPTO\_GOU) or MPEP 801.64. 2 Enter of thice that issued the document, by the Nov-letter of Kind Standard S13...) For Lispanese patent for comment, the middle contine the major comment process the sense in the Emperor may precede the sense in unwhere of the patent for which only the propriets emprisor as andicated on the document under WIPO Standard S11.68 if possible, 2 Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99) Art Unit

Application Number		10574384
Filing Date		
First Named Inventor	L. Wa	ing
Art Unit		
Examiner Name		
Attack Desirat North		CACHANTING

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate selection(s):
---------------	----------	----------	-------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 137(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Gary S. Kindness/	Date (YYYY-MM-DD)	2007-03-02
Name/Print	Gary S. Kindness	Registration Number	22178

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2211-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.